Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis. (EADV 2026) - "Pruritus‑NRS showed improvement over time, with statistically significant differences emerging at Week 8 (p=0.0021).Non‑head‑to‑head comparative benchmarking suggests that Week 12 EASI improvements with EVO301 align broadly with those reported for marketed AD biologics, including dupilumab, lebrikizumab, tralokinumab, and nemolizumab, when compared with published Phase 3 trials of differing designs and durations. Conclusion EVO301 met its primary and key secondary efficacy endpoints, produced rapid and sustained clinical improvements, demonstrated a favorable safety and tolerability profile, and showed clear biological activity. These results support further dose optimization and advancement into a Phase 2b dose‑ranging study using a subcutaneous formulation."

Clinical • Late-breaking abstract • P2a data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Respiratory Diseases • IL18

Real-world use of tralokinumab in patients with atopic dermatitis involving high-burden areas: Effectiveness and impact on quality of life in the prospective, non-interventional 12-month TRACE study (EADV 2026) - "Conclusions Among patients with multiple high-burden areas affected at baseline, over 70% demonstrated a reduction in high-burden involvement after 12 months of treatment. These sustained improvements were closely aligned with clinically meaningful gains in QoL, underscoring the substantial and long‑term patient benefit of tralokinumab in the management of difficult‑to‑treat AD."

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13

Real-world demographics, clinical characteristics, and itch burden of patients with atopic dermatitis and prurigo nodularis receiving advanced systemic therapy in Canada using Artificial Intelligence-extracted data (EADV 2026) - "Three nested panels were defined: (P1) all eligible patients; (P2) a subset of patients who initiated advanced systemic therapy (dupilumab; tralokinumab; lebrikizumab; upadacitinib; abrocitinib; baricitinib) on or after AD/PN diagnosis; and (P3) a subset of patients who initiated advanced systemic therapy and had documented itch any time after date of advanced systemic therapy initiation until date of last follow-up (last visit to the dermatologist before June 30, 2025). Nearly half of patients initiating advanced systemic therapy had documented itch sometime after initiation, which in several cases may suggest residual symptom burden associated with incomplete disease control and ongoing unmet need. AI-enabled EHR extraction provides scalable insight into disease control, symptom burden, and treatment patterns, supporting future evidence generation and care optimization."

Clinical • Metastases • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis • Pruritus

Dupi Next? Real-World Outcomes of Second- and Third-Line Systemic Therapy After Dupilumab in Pediatric Atopic Dermatitis (EADV 2026) - "Several alternative systemic agents approved for AD, including the IL-13 inhibitors- lebrikizumab and tralokinumab, and the oral JAK inhibitors- upadacitinib and abrocitinib, are now approved for pediatric populations. third-line response was modest (25%). Given the small, non-randomized sample, these findings warrant confirmation in larger prospective studies."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • IL13

Targeted Systemic Therapies for Head and Neck Atopic Dermatitis: A Systematic Review and Meta-Analysis of Efficacy and Safety (EADV 2026) - "Multiple electronic databases were systematically searched to identify randomized controlled trials and observational studies reporting outcomes in patients with head and neck AD treated with targeted systemic therapies, including dupilumab, tralokinumab, and upadacitinib. Differences in efficacy and safety support individualized, mechanism-driven treatment selection. However, significant heterogeneity and the absence of direct comparisons highlight the need for head-to-head trials and standardized outcomes to optimize management and guide precision-based care."

Retrospective data • Review • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Herpes Zoster • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Varicella Zoster

Treatment Outcomes and Failure Patterns in Multi-Refractory Atopic Dermatitis: A Single-Centre Descriptive Study (EADV 2026) - "Therapeutic failure occurred in 45 cases: 25 primary failures (predominantly with dupilumab and tralokinumab) and 20 secondary failures (mainly with upadacitinib and baricitinib). To our knowledge, few studies have specifically focused on patients receiving three or more advanced therapies. This descriptive analysis of multi-refractory cases underscores the need for predictive biomarkers and long-term efficacy data to optimize therapeutic sequencing in this challenging population."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Prurigo Nodularis • Pruritus

Preliminary real-world patient-reported outcomes and mHealth engagement with lebrikizumab in moderate-to-severe atopic dermatitis: a multicenter ePROM study using the NAVETA platform (EADV 2026) - "Treatment was first-line in 44.4%, second-line in 40.7%, and third-line in 14.8%, (prior dupilumab n=12, tralokinumab n=6). Baseline ePROM completion (35.3%) highlights the need for strategies to enhance early digital engagement. Data source: NAVETA mHealth platform – All numbers verified against raw CSV data.Hospitals: H.U. Son Espases (n=8), H.C. d'Inca (n=9), H. de Manacor (n=6), H. Mateu Orfila (n=3), H.G. de Tomelloso (n=1)."

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Atopic Dermatitis • CNS Disorders • Depression • Dermatitis • Dermatology • Immunology • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Ophthalmology • Pruritus • Sleep Disorder • IL13

Drug survival in adult atopic dermatitis patients in the TREATgermany registry (EADV 2026) - "The registry includes now sufficiently long follow-up periods for other systemic therapies (STs) used in adult patients with moderate to severe atopic dermatitis (i.e., abrocitinib, lebrikizumab, tralokinumab, upadacitinib). While multiple explanations are possible, this finding does not necessarily indicate reduced effectiveness of dupilumab. Rather, it is plausible that changes in prescribing behavior - such as a lower threshold for switching therapies in the presence of available alternatives - have contributed to the observed pattern."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Cardiovascular Risk Assessment Using SCORE2 in Patients Aged 40 - 69 Years with Atopic Dermatitis: A Case - Control Study (EADV 2026) - "Topical corticosteroids, emollients, and systemic agents—such as dupilumab, tralokinumab, JAK inhibitors, and conventional immunosuppressants—are commonly used to control disease symptoms. Table 1 – Baseline demographic and clinical characteristics of patient and healthy groups Conclusions Our study substantiates current literature demonstrating a heightened risk of cardiovascular disease in atopic dermatitis patients, uniquely quantified in this study by using the standardized SCORE2 tool. These findings underscore the need for clinicians to implement early preventive measures and consider proactive cardiology consultations for patients older than 40 years, presenting with cardiac risk factors or symptoms."

Clinical • Asthma • Atopic Dermatitis • Cardiovascular • Congestive Heart Failure • Dermatitis • Dermatology • Food Hypersensitivity • Heart Failure • Hypertension • Immunology • Myocardial Infarction • Respiratory Diseases • IL33 • IL6 • TSLP

COMBINED BIOLOGIC AND JANUS KINASE INHIBITOR THERAPY FOR RECALCITRANT SEVERE ATOPIC DERMATITIS: A REAL-WORLD CASE SERIES (EADV 2026) - "Patient characteristics, previous systemic treatments and severity scores Results Eleven patients were included in the study (6 female and 5 male, average age 26.6, range 21-48) who had failed multiple prior systemic therapies, including ciclosporin, methotrexate, and monotherapy biologics or JAKi. Combination therapies included dupilumab and upadacitinib (n=3), lebrikizumab and abrocitinib (n=4), lebrikizumab and upadacitinib (n=1), tralokinumab and abrocitinib (n=2) and tralokinumab and upadacitinib (n=1)...In our cohort, combined biologic and JAKi therapy appear to be an effective and generally well-tolerated option for patients with recalcitrant, severe, AD who have failed or been intolerant of conventional systemic therapies and biologic/JAKi monotherapy. Larger prospective studies are needed to establish long-term safety, durability of response and treatment sequency strategies."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Ophthalmology • Pruritus • Urticaria

Treatment persistence and switching patterns of targeted therapies in moderate-to-severe atopic dermatitis: an episode-level real-world cohort study (EADV 2026) - "Drug-specific 12-month estimates were 76.1% (95% CI 69.9-81.2) for dupilumab, 59.3% (95% CI 48.0-69.0) for upadacitinib 30 mg, 40.6% (95% CI 26.6-54.1) for tralokinumab, and 21.3% (95% CI 10.6-34.6) for upadacitinib 15 mg. In this real-world cohort, biologics showed higher 12-month persistence than JAK inhibitors, and switching clustered around dose adjustment and post-dupilumab treatment changes. These findings may help contextualise longer-term treatment pathways in routine care."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparative Efficacy of Dupilumab, Tralokinumab, and Lebrikizumab on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A Frequentist Network Meta-Analysis (EADV 2026) - "These findings should be interpreted as exploratory and directional given the inherent limitations of indirect comparisons and the modest evidence base. Nevertheless, they provide a meaningful framework to guide individualised treatment decisions in moderate-to-severe AD, pending direct head-to-head trial data."

Patient reported outcomes • Retrospective data • Atopic Dermatitis • CNS Disorders • Depression • Dermatitis • Dermatology • Immunology • Mood Disorders • Pruritus • Sleep Disorder • IL13 • IL4

Longitudinal laboratory profile of patients with moderate-to-severe atopic dermatitis treated with lebrikizumab or tralokinumab in real-world clinical practice (EADV 2026) - "These findings support the favourable analytical safety profile of IL-13 inhibitors in routine practice. Comparative efficacy results should be interpreted cautiously due to the observational design, baseline differences and limited sample size at later visits."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13

Effectiveness and Safety of Tralokinumab in Korean Patients with Atopic Dermatitis: A Multicenter Retrospective Study (EADV 2026) - "Adverse events were reported in 34.8% of patients, with AD exacerbation being the most common. Conclusions Tralokinumab demonstrated sustained effectiveness and an acceptable safety profile in Korean patients with moderate-to-severe AD in a real-world setting."

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Evidence that IL-4/IL-13-Responsive IGFLs Promote Allergic Skin Inflammation. (PubMed, J Invest Dermatol) - "In vivo experiments also demonstrated that Igfl induction is dependent on IL-4Rα in the Oxa model, and AD patients who received dupilumab or tralokinumab treatment showed decreased IGFL4 expression in lesional skin. These data suggest there is a positive feedback loop between IL-4/IL-13 and IGFLs that can promote allergic skin inflammation."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IFNG • IGF1 • IL13 • IL4

Real-life retrospective study of advanced systemic therapies in patients with chronic hand eczema: patient profile, drug effectiveness and safety. (EADV 2026) - "Results 103 patients were treated with 112 therapies, including dupilumab (n=65), tralokinumab (n=16), upadacitinib (n=13), abrocitinib (n=13) and baricitinib (n=5). Adverse effects were observed in 16 patients (15.5%), but only resulted in drug discontinuation in 4 patients. Conclusions Daily-practice data may support the favorable effectiveness and safety of advanced systemic options for patients with moderate-to-severe CHE."

Metastases • Retrospective data • Contact Dermatitis • Dermatology • Immunology

A biomarker of type VII collagen degradation is correlated with EASI and decreases after 12 weeks of abrocitinib and baricitinib treatment in patients with atopic dermatitis (EADV 2026) - "Materials and Methods The immunoassay C7M was measured in serum from 40 AD patients receiving Dupilumab (300 mg bi-weekly, n = 16), Tralokinumab (300 mg bi-weekly, n = 5), Abrocitinib (200 mg/day, n =14) or Baricitinib (4 mg/day, n = 5). However, percentage change did not differ significantly between responders and non-responders in either treatment group (p = 0.20 and p = 0.14, respectively). Conclusions These exploratory findings suggest that C7M may be associated with disease severity and could have potential as a biomarker of treatment response to JAK inhibitory therapy in AD, although this requires confirmation in larger studies."

Biomarker • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL4

Effectiveness of Lebrikizumab as a switch from Tralokinumab in patients with moderate-to-severe atopic dermatitis: a real-world case series (EADV 2026) - "Prior systemic therapies included topical corticosteroids (8/8), ciclosporin (6/8) and dupilumab (2/8), with a median tralokinumab duration before switching of 32 weeks (range 20–92). This evidence is further consolidated by the single-centre retrospective study from the same group (BioDrugs 2026, n=16), which demonstrated EASI 50 and EASI 75 rates of 91.7% and 83.3% respectively at week 48, with sustained improvement and a favourable safety profile. We present a real-world case series that expands the available evidence on switching from tralokinumab to lebrikizumab, suggesting that this strategy can be effective in patients with moderate-to-severe AD refractory to the former."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13

Lebrikizumab-associated ocular surface disease in atopic dermatitis patients: a prospective study from the BioDay registry (EADV 2026) - "Patients were categorized as biologic-naive and biologic-experienced based on prior treatment with dupilumab and/or tralokinumab. Conjunctival GC numbers remained stable during 28 weeks of lebrikizumab treatment. Overall, these findings underscore the need for dermatologists to be aware of LAOSD in AD patients treated with lebrikizumab."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Ocular Inflammation • Ophthalmology

RECLASSIFYING PLACEBO: A SYSTEMATIC REVIEW AND META-REGRESSION OF PLACEBO RESPONSE MAGNITUDES ACROSS PHASE 3 TRIALS IN PRURIGO NODULARIS AND ATOPIC DERMATITIS (EADV 2026) - "Materials and Methods A systematic search of ClinicalTrials.gov, PubMed, and EMBASE (2015–2026) identified 23 phase 3 randomized controlled trials (n=11,247 patients): 12 in AD (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and 11 in PN (nemolizumab, dupilumab, vixarelimab). A proposed placebo-response-based classification threshold (30%) may help distinguish neural-predominant from immune-predominant disease drivers in early-phase trials. These findings argue for reclassifying placebo not as noise but as a potential surrogate marker for underlying pathophysiology."

Clinical • P3 data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis

Lebrikizumab improves clinical outcomes and reduces serum TARC in biologic-naive and biologic-experienced patients with atopic dermatitis: 16-week real-world data from the BioDay Registry (EADV 2026) - "Overall, 57 patients (44.2%) were biologic-experienced, having previously received dupilumab and/or tralokinumab. Improvements were observed in across biologic-experienced and biologic-naïve subgroups and was accompanied by a marked reduction in serum TARC levels. Although treatment discontinuation due to AEs was low and most AEs were mild-to-moderate, severe ocular surface disease occurred in a small number of patients."

Clinical • Clinical data • Real-world • Real-world evidence • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • IL13

Real-World Impact of Achieving Optimal Versus Moderate Treatment Targets on Patient Outcomes: Analysis of the PPD CorEvitas Atopic Dermatitis Registry (EADV 2026) - "Materials and Methods This analysis includes participants from the PPD TM CorEvitas TM AD Registry who initiated an advanced systemic therapy (AST; dupilumab, tralokinumab, lebrikizumab, nemolizumab, abrocitinib, or upadacitinib) and maintained that therapy at their 6-month follow-up visit. When considering simultaneous skin & itch improvement, response rates were 70% to 96% for those who reported MDA (EASI 90 to 100 & PP-NRS 0 to 1) compared to 25% to 61% for those who reported the moderate target (EASI 75 to 89 & PP-NRS improvement ≥4). Conclusions These real-world findings suggest that meeting optimal, rather than moderate, skin and itch treatment targets is associated with meaningfully better patient outcomes at 6 months in AD."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Biologics versus JAK Inhibitors in Atopic Dermatitis: Baseline Data from the German ADBest-TREAT Registry (EADV 2026) - "Among patients receiving biologics, Dupilumab was the most commonly used treatment (n=106), followed by Lebrikizumab (n=60), Tralokinumab (n=24), and Nemolizumab (n=1)...Among the patients who were newly prescribed a JAKi (n=35), previous therapy most commonly included Dupilumab (n=13), Upadacitinib (n=3), Abrocitinib (n=2), and Tralokinumab (n=2)...Among patients who were newly treated with biologics (n=191), most frequent prior treatments were Dupilumab (n=18), Tralokinumab (n=8), Baricitinib (n=3), Lebrikizumab (n=2), and Upadacitinib (n=1)...Overall, clear guideline-based treatment patterns were observed, reflecting a high-quality care. Continued data collection and further analyses are essential to better understand the factors driving physicians' preference for biologics versus JAKi and the differential choices among JAKi in routine practice."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Methotrexate enhances the efficacy of tralokinumab in severe atopic dermatitis. (EADV 2026) - "The first patient is a 58-year-old man with severe atopic dermatitis since early childhood, chronic hepatitis B treated with Entecavir, inoperable bilateral cataracts, a history of hypertension and contact allergy. Due to the condition of his skin, he had been treated repeatedly with short courses of systemic steroid therapy and cyclosporine...The patient continues monotherapy with tralokinumab. Conclusion In patients with severe atopic dermatitis treated with tralokinumab, the temporary addition of methotrexate allows for faster remission of skin lesions."

Clinical • Atopic Dermatitis • Cardiovascular • Cataract • Dermatitis • Dermatology • Hepatitis B • Hepatology • Hypertension • Immunology • Infectious Disease • Ophthalmology • Pruritus • IL13

Comparative Safety of Biologics in Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis (EADV 2026) - "Lebrikizumab was associated with fewer TEAEs (RR 0.84, 95% CI 0.72–0.97), while dupilumab and tralokinumab showed no significant differences. Current evidence is limited by short follow-up and low event rates. Treatment decisions should consider factors beyond short-term safety, including efficacy and patient preferences."

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL4